T. Rowe Price Associates
THRD

T. Rowe Price Associates’s Third Harmonic Bio THRD Stock Holding History

T. Rowe Price Associates’s Portfolio THRD Stock Details THRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,811
Closed -$65K – 3125
2025
Q2 		$65K Buy
+11,811
New +$58.9K ﹤0.01% 2968
2025
Q1 		– Sell
-361,890
Closed -$3.73M – 3077
2024
Q4 		$3.73M Buy
+361,890
New +$4.51M ﹤0.01% 1370
2023
Q1 		– Sell
-457,327
Closed -$1.97M – 2949
2022
Q4 		$1.97M Sell
457,327
-13,299
-3% -$223K ﹤0.01% 1468
2022
Q3 		$8.93M Buy
+470,626
New +$8.48M ﹤0.01% 1082

Other funds holding THRD

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
AB
Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

T. Rowe Price Associates's THRD Position: Q3 2025 in Review

T. Rowe Price Associates sold out of Third Harmonic Bio (THRD) in Q3 2025, closing a stake of 11,811 shares — an estimated $65K sold.

T. Rowe Price Associates first reported a position in THRD in Q3 2022 and held it in 4 quarters. The position peaked at $8.93M in Q3 2022. 18 funds tracked by Wall St. Rank hold THRD as of Q3 2025.

  • T. Rowe Price Associates reported no remaining Third Harmonic Bio position as of Q3 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 11,811 Third Harmonic Bio shares in Q3 2025, an estimated $65K.
  • T. Rowe Price Associates first reported a position in Third Harmonic Bio in Q3 2022 and held it in 4 quarters.
  • T. Rowe Price Associates's Third Harmonic Bio position peaked at $8.93M in Q3 2022.
  • 18 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q3 2025.

Based on T. Rowe Price Associates's 13F filing for Q3 2025, filed 14 Nov 2025.